Nothing Special   »   [go: up one dir, main page]

EA201400950A1 - Способы распространения комплемент-ингибирующих лекарственных средств среди пациентов, получающих ингибитор комплемента - Google Patents

Способы распространения комплемент-ингибирующих лекарственных средств среди пациентов, получающих ингибитор комплемента

Info

Publication number
EA201400950A1
EA201400950A1 EA201400950A EA201400950A EA201400950A1 EA 201400950 A1 EA201400950 A1 EA 201400950A1 EA 201400950 A EA201400950 A EA 201400950A EA 201400950 A EA201400950 A EA 201400950A EA 201400950 A1 EA201400950 A1 EA 201400950A1
Authority
EA
Eurasian Patent Office
Prior art keywords
complete
patients
methods
distributing
inhibitor
Prior art date
Application number
EA201400950A
Other languages
English (en)
Russian (ru)
Inventor
Леонард Белл
Original Assignee
Алексион Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алексион Фармасьютикалс, Инк. filed Critical Алексион Фармасьютикалс, Инк.
Publication of EA201400950A1 publication Critical patent/EA201400950A1/ru

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00ICT specially adapted for the handling or processing of medical references
    • G16H70/40ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04CROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
    • F04C2270/00Control; Monitoring or safety arrangements
    • F04C2270/04Force
    • F04C2270/041Controlled or regulated

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201400950A 2012-03-16 2012-03-16 Способы распространения комплемент-ингибирующих лекарственных средств среди пациентов, получающих ингибитор комплемента EA201400950A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/029499 WO2013137912A2 (fr) 2012-03-16 2012-03-16 Méthodes de distribution de médicaments inhibant le complément aux patients recevant un inhibiteur de complément

Publications (1)

Publication Number Publication Date
EA201400950A1 true EA201400950A1 (ru) 2014-12-30

Family

ID=49161929

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400950A EA201400950A1 (ru) 2012-03-16 2012-03-16 Способы распространения комплемент-ингибирующих лекарственных средств среди пациентов, получающих ингибитор комплемента

Country Status (6)

Country Link
EP (1) EP2825989A4 (fr)
CN (1) CN104205155A (fr)
EA (1) EA201400950A1 (fr)
HK (1) HK1204693A1 (fr)
IL (1) IL234680A0 (fr)
WO (1) WO2013137912A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2930544A1 (fr) * 2013-11-13 2015-05-21 Shire Viropharma Incorporated Utilisations d'inhibiteur de c1-esterase pour le traitement de la neuromyelite optique et des maladies du spectre de la neuromyelite optique, et compositions le comprenant
CN105260974A (zh) * 2015-09-10 2016-01-20 济南市儿童医院 一种生成具有告签功能的电子病历方法及系统
CN115177291B (zh) * 2022-08-01 2023-11-10 首都医科大学附属北京朝阳医院 用于识别重症监护病房获得性肌无力的方法和装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315720B1 (en) * 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US20040117126A1 (en) * 2002-11-25 2004-06-17 Fetterman Jeffrey E. Method of assessing and managing risks associated with a pharmaceutical product
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20060062734A1 (en) * 2004-09-20 2006-03-23 Melker Richard J Methods and systems for preventing diversion of prescription drugs
HUE030105T2 (en) * 2006-03-15 2017-04-28 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobin uptake with complement inhibitor
US8478605B2 (en) * 2006-07-17 2013-07-02 Walgreen Co. Appropriateness of a medication therapy regimen
WO2008021954A2 (fr) * 2006-08-09 2008-02-21 Biogen Idec Ma Inc. Procédé de distribution d'un médicament
PL2894165T3 (pl) * 2008-11-10 2023-04-17 Alexion Pharmaceuticals, Inc. Sposoby i kompozycje do leczenia zaburzeń układu dopełniacza
US8362210B2 (en) * 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity

Also Published As

Publication number Publication date
CN104205155A (zh) 2014-12-10
EP2825989A4 (fr) 2016-01-06
HK1204693A1 (en) 2015-11-27
WO2013137912A3 (fr) 2014-05-01
EP2825989A2 (fr) 2015-01-21
WO2013137912A2 (fr) 2013-09-19
IL234680A0 (en) 2014-11-30

Similar Documents

Publication Publication Date Title
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015018168A2 (pt) inibidores de rock suaves
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112012022552A8 (pt) uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
CL2014002935A1 (es) Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
EA201590726A1 (ru) Лахинимод для уменьшения таламического поражения при рассеянном склерозе
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
EA201491427A1 (ru) Замещенные фенилимидазопиразолы и их применение
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA201400950A1 (ru) Способы распространения комплемент-ингибирующих лекарственных средств среди пациентов, получающих ингибитор комплемента
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
EA201591603A1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
EA201301275A1 (ru) Соединения, фармацевтические композиции и способ профилактики и лечения спаечного процесса
BR112015007095A8 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados